148 related articles for article (PubMed ID: 30182245)
21. [G-DRG Version 2008: Facts and analyses].
Müller ML; Forschner A; Wenke A; Luger TA; Rompel R; Roeder N; Hensen P
J Dtsch Dermatol Ges; 2008 Jun; 6(6):483-91. PubMed ID: 18494710
[No Abstract] [Full Text] [Related]
22. Radiation Oncology in Oman: Current Status and Future Challenges.
Al Balushi M; Al Mandhari Z
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):851-855. PubMed ID: 32665111
[TBL] [Abstract][Full Text] [Related]
23. [Suggestions for implementation of DRG in the fields of Orthopaedics and Trauma Surgery for 2004].
Roeder N; Franz D; Siebert H; Frank D; Stücker R; Meiners T; Tempka A; Siebert CH
Z Orthop Ihre Grenzgeb; 2003; 141(4):379-85. PubMed ID: 12928992
[TBL] [Abstract][Full Text] [Related]
24. Value-based health care - what does it mean for radiotherapy?
Lievens Y; Grau C; Aggarwal A
Acta Oncol; 2019 Oct; 58(10):1328-1332. PubMed ID: 31379232
[No Abstract] [Full Text] [Related]
25. The Hanover Consensus: helpful for German decision-makers?
Kolominsky-Rabas PL; Caro JJ
Value Health; 2008; 11(4):545-6; discussion 547-8. PubMed ID: 18489522
[No Abstract] [Full Text] [Related]
26. The Resilience of Radiation Oncology in the COVID Era and Beyond.
Teckie S; Koffler D; Potters L
Int J Radiat Oncol Biol Phys; 2020 Oct; 108(2):364-369. PubMed ID: 32890514
[No Abstract] [Full Text] [Related]
27. Radiation oncology in the third millennium.
Brady LW; Levitt SH
Rays; 1999; 24(3):361-72. PubMed ID: 10605296
[TBL] [Abstract][Full Text] [Related]
28. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus.
Graf von der Schulenburg JM; Greiner W; Jost F; Klusen N; Kubin M; Leidl R; Mittendorf T; Rebscher H; Schoeffski O; Vauth C; Volmer T; Wahler S; Wasem J; Weber C;
Value Health; 2008; 11(4):539-44. PubMed ID: 18194408
[No Abstract] [Full Text] [Related]
29. [The cost estimator in the TraumaRegister DGU].
Lefering R; Mahlke L; Franz D
Unfallchirurg; 2017 Dec; 120(12):1065-1070. PubMed ID: 27785521
[TBL] [Abstract][Full Text] [Related]
30. [DRG-based cost analysis of inpatient conservative treatment of stage III/IV peripheral arterial occlusive disease].
Heidrich H; Rogatti W; Altmann E; Bauersachs R; Diehm C; Fahrig C; Lawall H; Ranft J; Schenker M; Schweizer HJ; Stiegler H; Wilke M
Vasa; 2003 Nov; 32(4):235-40. PubMed ID: 14694775
[TBL] [Abstract][Full Text] [Related]
31. The possible impact of the German DRGs reimbursement system on end-of-life decision making in a surgical intensive care unit.
Stachura P; Oberender P; Bundscherer AC; Wiese CH
Wien Klin Wochenschr; 2015 Feb; 127(3-4):109-15. PubMed ID: 25622109
[TBL] [Abstract][Full Text] [Related]
32. [DRG reimbursement for multiple trauma patients -- a comparison with the comprehensive hospital costs using the German trauma registry].
Grotz M; Schwermann T; Lefering R; Ruchholtz S; Graf v d Schulenburg JM; Krettek C; Pape HC
Unfallchirurg; 2004 Jan; 107(1):68-75. PubMed ID: 14749855
[TBL] [Abstract][Full Text] [Related]
33. [Epidemiological research with data from cancer registries: a program financed by the German Cancer Aid (Deutsche Krebshilfe, DKH)].
Blettner M; Ludwig S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Jan; 57(1):47-51. PubMed ID: 24357172
[TBL] [Abstract][Full Text] [Related]
34. [Introduction of the DRG system in Germany: objectives, problems and perspectives on the basis of a lump sum payment from the perspective of the Federal Ministry of Health].
Rau F
Z Arztl Fortbild Qualitatssich; 2002 Aug; 96(8):498-504. PubMed ID: 12244869
[TBL] [Abstract][Full Text] [Related]
35. Reimbursement versus effort in medical physics practice in radiation oncology.
Herman MG; Mills MD; Gillin MT
J Appl Clin Med Phys; 2003; 4(2):179-87. PubMed ID: 12777154
[TBL] [Abstract][Full Text] [Related]
36. Conforming Modern Radiation Oncology Facilities to the Irregular Contours of the Vast and Varied Nation of India.
Kannan V; Bajpai R
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):645-51. PubMed ID: 26972637
[No Abstract] [Full Text] [Related]
37. HERO (Health Economics in Radiation Oncology): a pan-European project on radiotherapy resources and needs.
Lievens Y; Dunscombe P; Defourny N; Gasparotto C; Borras JM; Grau C
Clin Oncol (R Coll Radiol); 2015 Feb; 27(2):115-24. PubMed ID: 25467072
[TBL] [Abstract][Full Text] [Related]
38. Impact of Patient Stage and Disease Characteristics on the proposed Radiation Oncology Alternative Payment Model (RO-APM).
Waddle MR; Stross WC; Vallow LA; Naessens JM; White L; Meier S; Spaulding AC; Buskirk SJ; Trifiletti DM; Keole SR; Ma DJ; Bajaj GK; Laack NN; Miller RC
Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):905-911. PubMed ID: 32001382
[TBL] [Abstract][Full Text] [Related]
39. Technology watch: proton beam therapy: is the market ready?
Reeder L
Healthc Leadersh Manag Rep; 2000 Aug; 8(8):6-10. PubMed ID: 11187344
[No Abstract] [Full Text] [Related]
40. [DRG projects of DGVS: big expectations, too little engagement?].
Zeitz M
Z Gastroenterol; 2008 May; 46(5):407-8. PubMed ID: 18461514
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
